Drug intelligence / Profile preview

MSP105

Development stage: Preclinical
Lead developer: Methapharm
Modality: Small Molecules

Overview

MSP105 is a central nervous system (CNS) drug candidate currently in development by Methapharm, a specialty pharmaceutical company. As of 2024, the product is listed in the company's pipeline with a projected target launch date of 2025. While the specific therapeutic indication and molecular mechanism of action have not been publicly disclosed, the drug is part of Methapharm's expansion into the CNS therapeutic area. Methapharm typically focuses on niche specialty medicines and diagnostic products, suggesting MSP105 may be a specialized therapeutic or a reformulated agent targeting a specific CNS condition.

Beyond the preview

Go deeper on MSP105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSP105.

Explore the full profile